Literature DB >> 11143231

Gamma knife radiosurgery for prolactinomas.

A M Landolt1, N Lomax.   

Abstract

OBJECT: In this retrospective investigation the authors examined the results of gamma knife radiosurgery (GKS) for tumor remnants after unsuccessful open surgery and medical treatment in 20 patients with prolactinomas. Particular attention is paid to a possible radioprotective action of dopamine agonists similar to the action of octreotide in acromegaly.
METHODS: Twenty patients with prolactinomas were followed after GKS. Five patients were treated successfully; their prolactin (PRL) levels dropped into the normal range and dopaminergic drugs could be discontinued. Two spontaneous pregnancies were observed and 11 patients experienced improvement. Improvement was defined as normal PRL levels with the continued possibility of reduced medical treatment or a substantially reduced medical treatment dose with some degree of hyperprolactinemia maintained. The treatment failed in three patients who experienced no improvement. Patients treated with dopaminergic drugs during GKS did significantly less well in comparison with the untreated group when a cumulative distribution function (Kaplan-Meier estimate) was used.
CONCLUSIONS: The results of GKS for prolactinomas in this investigation are better than the results published by others. This may be an effect of case selection because there were no "salvage cases" in our group of patients. Because a dopamine agonist seemed to induce radioprotection in this series, it is suggested that GKS be performed during an intermission in drug therapy when the dopamine agonist is discontinued.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11143231     DOI: 10.3171/jns.2000.93.supplement

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  30 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Samuel Shin; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

Review 3.  Role of stereotactic radiosurgery in the management of pituitary adenomas.

Authors:  Frederic Castinetti; Jean Régis; Henry Dufour; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2010-02-23       Impact factor: 43.330

Review 4.  Stereotactic radiosurgery of benign intracranial tumors.

Authors:  Bruce E Pollock
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 5.  Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.

Authors:  Dale Ding; Robert M Starke; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-05       Impact factor: 4.130

Review 6.  Radiation techniques in neuro-oncology.

Authors:  Deepak Khuntia; Wolfgang A Tomé; Minesh P Mehta
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 7.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

Review 8.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 9.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 10.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.